Akero Therapeutics, Inc.

NasdaqGS:AKRO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 4.49 B

Share Price

USD 56.28

Avg Daily Volume

1,443,244

Change (1 day)

2.25%

Change (1 year)

145.44%

Change (YTD)

102.30%

Akero Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD -0.00

Akero Therapeutics, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending March 31, 2025, a -100.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.

Akero Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 6.06.
Akero Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -0.00.
Akero Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -0.00.
Akero Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Dividend Per Share	Debt to Equity Ratio	Quick Ratio	Current Ratio

NasdaqGS: AKRO

Akero Therapeutics, Inc.

CEO	Dr. Andrew Cheng M.D., Ph.D.
IPO Date	June 20, 2019
Location	United States
Headquarters	601 Gateway Boulevard
Employees	69
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.